Login or Register to unlock everything MedSchool has to offer!

Monoclonal Antibodies

 
 
 
Immunotherapy
Haematologic Malignancies
Solid Organ Malignancies
Other
 
 

Anti-PD-L1 Antibodies

 
 
  •  
    IV infusion
    Atezolizumab
    Tecentriq 
  •  
    IV infusion
    Durvalumab
    Imfinzi 
  •  
    IV infusion
    Avelumab
    Bavencio 
    • Mechanism of Action
    • Monoclonal antibodies directed against PD-L1, an inhibitory molecule expressed on certain tumour cells.
    • PD-L1 and PD-L2 are ligands that bind to PD-1 receptors on activated lymphocytes and inhibit T cell receptor signalling, downregulating immune responses and promoting tolerance.
    • Binding of anti-PD-L1 monoclonal antibodies leaves the ligand unable to bind to PD-1, and therefore stimulates an ongoing immune response.
  • PD-L2 is not inhibited, allowing PD-1 / PD-L2 mediated inhibitory signals to continue

Clinical Use

    • Indications
    • Locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression post chemotherapy / targeted therapy (atezolizumab)
    • Locally advanced non-small cell lung cancer (NSCLC) without progression post chemoradiotherapy (durvalumab)
    • Locally advanced or metastatic urothelial carcinoma with progression post platnium-based chemotherapy (durvalumab)
    • Metastatic Merkel cell carcinoma (avelumab)
    • Adverse Effects
    • Immune-Related
    • Endocrinopathies - thyroiditis, adrenalitis, hypophysitis, diabetes mellitus
    • Pulmonary toxicity - pneumonitis
    • Hepatotoxicity - LFT derangement, hepatitis
    • GI toxicity - colitis
    • Rheumatological - flares of previous disease
    • Skin - rash, pruritis
    • Other
    • Fatigue
    • Anorexia
    • Headache
    • Dizziness
    • Nausea / vomiting / diarrhoea
    • Thrombocytopaenia
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback